P2.19-01 First-in-Human Phase 1 Trial of VT3989, a First-in-Class YAP/TEAD Inhibitor in Patients with Advanced Mesothelioma
Timothy A. Yap, Jayesh Desai, Ibiayi Dagogo‐Jack, Michael Millward, Hedy L. Kindler, Anthony W. Tolcher, Sophia Frentzas, Amy Body, Alexander J F Thurston, Leonard Post, F. Andrew Dorr, David J. Kwiatkowski
Topics & Concepts
Hippo signaling pathwayMesotheliomaMedicineCancer researchRegulatorEffectorPalmitoylationCell biologyBiologyGeneticsImmunologyPathologyGeneBiochemistryCysteineEnzymeOccupational and environmental lung diseasesHippo pathway signaling and YAP/TAZNuclear Structure and Function